ACTA SCIENTIAE

ISSN: 2178-7727
DOI: 10.17648/acta.scientiae.6369

A COMPREHENSIVE REVIEW ON ANTIDIABETIC POTENTIAL OF *ABIES WEBBIANA* LINDL.

Rupa Ganguly[1*], Dildar Husain[1], Priyanka Singh[2]
[1]School of Life and Basic Sciences, Jaipur National University, Jaipur, Rajasthan-302017s
[2]Department of Botany, Maharaja Suhel Dev University, Azamgarh, U.P.-276001
***Corresponding Author**
Rupa Ganguly
Research Scholar
School of Life and Basic Sciences,
Jaipur National University, Jaipur,
Rajasthan-302017, India
E-mail: rupamscsvpi@gmail.com

Abstract

The rise in the incidence of type 2 diabetes mellitus (T2DM) around the world highlights the critical need for non-synthetic therapy options that are safe, inexpensive, and capable of targeting multiple targets. The Himalayan medicinal conifer *Talisastra*, or *Abies webbiana*, has a long tradition of usage in Ayurvedic treatment of respiratory and metabolic diseases, and currently it has the potential to be a natural anti-diabetic. The phytochemical characteristics, pharmacological processes, and translational potential of this compound are examined in this detailed review. Studies from phytochemical studies show that the plant contains bioactive terpenoids (abienol, limonene, and camphene), flavonoids (quercetin and kaempferol), and phenolics (gallic and caffeic acids) that have significant anti-inflammatory, antioxidant, and enzyme-inhibitory effects. A study conducted in both experimental environments and computational models shows that the α-amylase, α-glucosidase, and DPP-IV enzymes are inhibited, insulin sensitivity is enhanced through the PI3K/Akt and AMPK pathways, and pancreatic β-cells are protected from oxidative stress. Network pharmacology and molecular docking have verified interactions with multiple targets, including important metabolic regulators such as PPARγ, AKT1, NF-κB, and SIRT1. The effects of reducing glucose, normalising lipids, and protecting tissues are further supported by in vivo animal models. However, there is a dearth of evidence on toxicity, absorption, and pharmacokinetics, which limits its application in clinical settings. These restrictions could be solved by integrating delivery systems based on nanotechnology with autonomous screening. The transition of *A. webbiana* from an ethnomedical practice to a treatment based on scientific data requires standardisation, safety profiling, and clinical validation. Collectively, the data presented here indicate that *A. webbiana* represents a promising botanical candidate for future generations of phytopharmaceuticals used to treat diabetes.

Keywords: Abies webbiana (Talis patra), Type 2 Diabetes Mellitus (T2DM), Anti-diabetic phytochemicals, Enzyme inhibition (α-amylase, α-glucosidase, DPP-IV), PI3K/Akt and AMPK pathways

1. Introduction

The global prevalence of Type 2 Diabetes Mellitus (T2DM) is rising rapidly, threatening the general population's health. There are numerous synthetic antidiabetic medicines, but extended usage can cause side effects, ineffectiveness, and economic difficulties. Thus, Natural alternatives with higher safety and multi-targeted therapeutic effects are in demand [1]. The Pinaceae species *Abies webbiana*, often known as Indian Silver Fir or Talispatra, has garnered attention. This plant has been used in Ayurvedic and Unani medicine to treat respiratory, digestive, and inflammatory issues.

It may also be used to treat diabetes. In this study, we critically assess the in vitro and in vivo evidence supporting the antidiabetic potential of *A. webbiana*, examine its phytochemical composition, explain its molecular mechanisms of action, and identify translational gaps that prevent its clinical use [2].

A comprehensive literature search was performed using PubMed, Scopus, Web of Science, and Google Scholar to identify pharmacological studies on *A. webbiana*. Only mechanistic or quantitative in vitro and in vivo research on antidiabetic, antioxidant, or cytoprotective activities was considered. The gathered data were organised by experimental models, phytoconstituents were analysed, results were observed, and the study quality was rigorously reviewed for scientific credibility.

A. webbiana contains several flavonoids, terpenoids, phenolics, and alkaloids, according to phytochemical studies. Abienol, limonene, and camphene are antioxidants and enzyme inhibitors that affect glucose metabolism and insulin signalling. Modern analytical methods, such as HPLC and LC-MS, have enabled the identification and quantification of these molecules, enabling pharmacodynamic analysis [3].

Several in vitro studies have explained the antidiabetic effects of *A. webbiana*. A key method involves the inhibition of carbohydrate-hydrolyzing enzymes, including α-amylase and α-glucosidase, which lowers postprandial glucose levels. These studies reported IC_{50} values that indicate strong enzyme-binding capacity, equivalent to or beyond conventional inhibitors like acarbose. *A. webbiana* extracts may also activate the PI3K/Akt signalling pathway to improve insulin sensitivity and glucose absorption in 3T3-L1 and L6 myotubes, respectively. The bioactive components of plants protect against streptozotocin (STZ) and alloxan-induced oxidative stress, preserving pancreatic β-cell viability and promoting insulin production. *A. webbiana* exhibits significant antioxidant and anti-glycation properties, as demonstrated by DPPH, ABTS, and advanced glycation end product (AGE) inhibition assays. It enhances glucose metabolism and maintains islet cell function [4].

In vivo studies on diabetic animal models, particularly STZ-induced diabetic rats, support the in vitro findings. These trials showed significant decreases in fasting blood glucose levels, improved lipid profiles, and restored β-cell morphology. Histopathological investigations suggest pancreatic tissue regeneration, whereas biochemical tests show hepatic and renal normalisation. These data indicate that the multi-targeted mechanisms of *A. webbiana* in vitro translate into biological efficacy in vivo, indicating its potential for diabetes treatment [5].

Despite promising outcomes, clinical application of findings from tests is challenging. The pharmacokinetic and pharmacodynamic characteristics and active chemical bioavailability of *A. webbiana* components have rarely been studied. Few toxicological studies have addressed acute or chronic toxicity profiles. Environmental and geographical conditions cause phytochemical content variability, which hinders reproducibility. For consistent efficacy and safety, extract preparation must be standardised and quality control measures must be established [6].

A. webbiana is a promising natural agent for controlling diabetes, including enzyme inhibition, antioxidant defence, β-cell protection, and insulin sensitisation. Additional study should identify molecular targets using in-silico and docking studies, develop standardised extracts using chromatographic markers, conduct comprehensive toxicity and dose-optimisation studies, and evaluate its long-term efficacy in well-designed preclinical and clinical trials to improve its translational potential. Traditional ethnomedicinal expertise, modern molecular pharmacology, and bioanalytical technologies could lead to safe and unique Abies webbiana-based diabetes treatments [7].

2. Traditional and Ayurvedic Therapeutic Significance of Abies webbiana (Talispatra)

A. webbiana (Talispatra) has substantial medicinal value in Ayurveda and is mentioned in traditional literature such as the Charaka Samhita and Sushruta Samhita, where it is used in numerous formulations for diseases such as Kasa (cough), Swasa (asthma), and Jwara (fever). The Sanskrit word "Talispatra", which translates to "fragrant leaf", refers to its distinct perfume and widespread use in aromatic and respiratory remedies. Traditionally, the leaves have been used in decoctions, powders, or inhalations to reduce respiratory congestion, stimulate expectoration, and alleviate breathing problems [8]. Beyond its respiratory applications, A. webbiana is highly regarded for its digestive-stimulating properties, serving as a deepana (appetiser) and pachana (digestive aid), while its anti-rheumatic and calming effects are attributed to the synergistic action of its volatile oil constituents, particularly the monoterpenes, which have soothing and anti-inflammatory properties [9].

In addition to regular Ayurvedic use, A. webbiana is central to the traditional medicine systems of Himalayan tribal communities, particularly in Uttarakhand, Himachal Pradesh, and Arunachal Pradesh, where the leaves and resin are used for various therapeutic purposes. Locals make herbal pastes and decoctions from the leaves and resin to cure bronchitis, wounds, and skin infections, and the smoke from burning leaves is often inhaled to treat coughs, colds, and nasal congestion. The resin paste is applied topically to relieve pain, inflammation, and joint discomfort, demonstrating strong analgesic and antiseptic properties. Both Ayurvedic and tribal medical traditions highlight the plant's varied healing potential, by emphasising its fragrant, antibacterial, anti-inflammatory, and regenerative characteristics, which contribute to its long-standing position as a valuable therapeutic agent in Indian ethnomedicine [10].

2.1. Comparative Ethnobotany and Bioactivity of Pinaceae Family Members

The Pinaceae family, which includes species such as Abies, Pinus, Cedrus, and Picea, has many similarities in how it has been used traditionally in different cultures for medicine. These plants have been used to treat breathing problems, inflammation, and microbial infections. Some of the species it includes, like Pinus roxburghii and Pinus longifolia, are very important in Unani and Siddha medicine [11]. Their resins and essential oils are used to treat asthma, gout, and wounds. Because it might assist with coughing, sore throat, and inflammation, the resin is often mixed into balms or ointments or used in steam inhalation. Similarly, Cedrus deodara, another important conifer in the family, is known to have strong pain-relieving, anti-inflammatory, and antioxidant properties. This is very similar to the medicinal profile of the Abies genus and shows the biochemical coherence of the family [12].

Abies pindrow and Abies spectabilis, both are close relatives of *A. webbiana*, are commonly used as tonics, expectorants, and antiseptics in the Himalayas. This shows how conifer-based remedies have been used for a long time and how cultures have changed them to fit mountain ecosystems. These Pinaceae species are used in many different traditional medicine systems, indicating that they have similar pharmacological properties. These similarities are based on comparable phytochemical structures [13]. These plants contain many monoterpenes, such as α-pinene and limonene, as well as sesquiterpenes and phenolic derivatives. These chemicals are known to kill germs, reduce inflammation, and protect cells from damage. Overall, this biochemical uniformity explains the therapeutic similarities observed among Pinaceae species. This indicates that their traditional ethnomedical uses come from a common source of bioactive constituents that act collectively in assisting with respiratory problems, inflammation, and infections.

2.2. Abies webbiana: Bridging Ayurvedic Wisdom and Modern Antidiabetic Mechanisms

Abies webbiana is mentioned as an antidiabetic remedy in classical Ayurvedic compendia, but its pharmacological properties include deepana (digestive stimulation), balya (strengthening and rejuvenating), and vatanulomana (regulation of bodily humor) which may help maintain metabolic equilibrium. Ayurveda links these traits to increased digestive efficiency, food assimilation, and physiological balance, which may indirectly prevent or treat metabolic issues. Oxidative stress, chronic inflammation, and metabolic dysregulation are major pathogenic variables in type 2 diabetes mellitus (T2DM), linking the traditional usage of *A. webbiana* to diabetic pathogenesis [14].

The antioxidant and anti-inflammatory properties of *A. webbiana* are one of the most direct mechanistic links. Flavonoids, phenolic acids, and terpenoids in the plant have powerful free radical-scavenging and cytokine-modulating properties. Bioactive chemicals neutralise ROS and inhibit inflammatory mediators that damage pancreatic β-cells and cause insulin resistance. *A. webbiana* could assist in maintaining glucose homeostasis and prevent diabetic complications by lowering oxidative stress and systemic inflammation, preserving β-cell integrity, enhancing insulin production, and improving peripheral insulin sensitivity [15].

Carbohydrate metabolism and enzyme inhibition are other possible mechanisms of action. Several Pinaceae species, such as *Abies pindrow* and *Cedrus deodara*, inhibit α-amylase and α-glucosidase enzymes, slowing carbohydrate digestion and lowering postprandial blood glucose levels. Although data for *A. webbiana* are limited, its phytochemical similarity to related species suggests that similar phenolic and terpenoid constituents could modulate carbohydrate metabolism by inhibiting enzymes or increasing glucose uptake in target tissues [16].

The historical use of *A. webbiana* as a stomachic and digestive tonic may also reflect its effects on the gastrointestinal tract and gut microbiota, which are now recognised as metabolic regulators. Plant essential oils and terpenoid chemicals may improve digestive enzyme secretion, intestinal motility, and microbial balance, thereby affecting glucose metabolism and insulin sensitivity. This gut-mediated regulation supports the current findings associating intestinal dysbiosis with insulin resistance and glucose intolerance [17].

A. webbiana's fragrant compounds, used in Ayurvedic fumigation (dhupa) and inhalation, may have mild but important neuroendocrine effects. By stimulating the hypothalamic–pituitary–adrenal (HPA) axis through olfactory stimulation, volatile components can affect stress responses and cortisol levels, which are linked to glucose metabolism and insulin regulation. The anxiolytic and restorative benefits of *A. webbiana's* scent may indirectly improve metabolic stability because chronic stress and high cortisol levels cause diabetes.

These biochemical and physiological interactions provide a consistent mechanistic link between the systemic tonic reputation of *A. webbiana* and its possible antidiabetic potential. Although its traditional uses focus on respiratory and digestive health, the convergence of antioxidant, anti-inflammatory, digestive, and neuroendocrine activities indicates that *A. webbiana* may be a complementary candidate for metabolic disorders, such as diabetes mellitus [18].

2.3. Bioactive Phytochemicals and Their Mechanistic Roles in *Abies webbiana*

The various phytochemicals that are present in abundance in Abies webbiana are a major factor in the plant's many medicinal uses. The plant's powerful antioxidant, anti-inflammatory, antibacterial, and antidiabetic actions are due to its flavonoids, phenolic chemicals, terpenoids, alkaloids, tannins, and glycosides. The essential oils that inhabit the resin and leaves are especially rich in monoterpenes, such as α-pinene and limonene, which are chemicals that are renowned for their bioactive activities.

The immune system, glucose metabolism, and oxidative stress are positively affected by the combined effects of these phytoconstituents. Absienol, limonene, and camphene are three of the most promising bioactive chemicals with antidiabetic potential, based on their structural similarities. The diterpene alcohol abienol modulates glucose transport routes, leading to insulin sensitisation. Through its antioxidant and anti-inflammatory properties, limonene, a cyclic monoterpene, enhances pancreatic β-cell activity and decreases hyperglycemia. Another monoterpene with potential as an adjuvant anti-diabetic chemical is camphene, which helps regulate lipid profiles and improves glucose utilisation [19].

A. webbiana contains lignans and diterpenoids that have anticancer and cytoprotective effects, in addition to these extensively researched substances. By lowering inflammation and encouraging a balanced gut microbiota, the combination of tannins and saponins further increases their function as digestive aids, improving gastrointestinal health. In addition to its long tradition of use as an aromatic and sedative, the monoterpenes in this plant work synergistically to alleviate respiratory distress, anxiety, and neuroprotection.

The development of standardised herbal medicines has been made possible by the accurate identification and quantification of these phytoconstituents, made possible by current analytical techniques such as GC-MS and HPLC. Abies webbiana is a valuable natural source of bioactive chemicals for medicinal, nutraceutical, and pharmaceutical applications owing to its complex chemical profile and active ingredients. The pharmaceutical effectiveness, safety, and molecular mechanisms, as well as their evidence-based incorporation into contemporary healthcare systems, must be confirmed through extensive in vivo and clinical investigations [20].

2.4. Structure–Activity Correlations of *Abies webbiana* Phytochemicals in Diabetes Management

Phenolics, flavonoids, terpenoids, and saponins qualify *Abies webbiana's* phytochemical substances as rich and diverse, contributing to its broad therapeutic spectrum. The simple phenols, phenolic acids and their derivatives in plants provide antioxidants and free radical scavengers to protect cellular components from oxidative stress, a major cause of type 2 diabetes mellitus. Quercetin, kaempferol, and their glycosidic derivatives are potent antioxidants, enzyme inhibitors, and anti-inflammatory flavonoids. These compounds enhance insulin secretion, improve peripheral glucose absorption, and inhibit lipid peroxidation, correlating with contemporary glycaemic control drugs [18].

An important aspect of A. webbiana's essential oils is their terpenoid component, which contains bioactive monoterpenes and diterpenes. Key terpenoids, including limonene, camphene, borneol, α-pinene, β-pinene, and abienol, contribute to its scent and pharmacological efficacy. These chemicals have anti-inflammatory, antioxidant, antibacterial, and metabolic regulating activities. Abienol, a labdane-type diterpene, modifies cytokine signalling and inhibits reactive oxygen species to reduce inflammation and protect cells. Laboratory diterpenes exhibit structural similarities to various plant-derived compounds that affect insulin receptor signalling and glucose transporter expression, indicating antidiabetic activity.

Limonene, a cyclic monoterpene found in *A. webbiana* essential oils, is hypoglycemic and lipid-lowering. Some limonene-rich botanicals have been shown to increase hepatic glucose metabolism, reduce pancreatic oxidative stress, and modify adipokine activity, thereby reducing insulin resistance. Camphene, another volatile ingredient, has strong antioxidant properties, reduces lipid peroxidation, and improves serum lipid profiles in diabetic animal models, indicating that it may regulate metabolism [21].

Advances in high-throughput analytical techniques, such as LC-MS and GC-MS, have enabled exhaustive phytochemical matrix profiling of *A. webbiana*. LC-MS investigations have revealed a diverse array of low-molecular-weight polyphenols, terpenoids, and flavonoid glycosides, highlighting the diversity and abundance of its bioactive components. High-resolution approaches assist in identifying and measuring compounds and correlating molecular profiles with biological effects, including antioxidant and enzyme-inhibitory activities, in metabolomic correlation studies. However, the saponin fraction of *A. webbiana* may have a significant effect on glucose metabolism. The amphiphilic properties of saponins affect cell membranes, cholesterol absorption, lipid metabolism, and insulin sensitivity. The presence of these compounds in the phytochemical repertoire of plants may enhance their metabolic and anti-inflammatory properties.

Phenolics, flavonoids, terpenoids, and saponins work together to make *A. webbiana* a versatile medicinal plant. Abienol, limonene, and camphene are particularly structurally diverse, providing a rational foundation for future structure–activity relationship (SAR) and molecular docking studies to determine their precise roles in modulating glucose homeostasis-related enzymatic and signalling pathways. Thus, complete LC-MS-guided phytochemical characterisation and in vitro and in silico validation will accelerate the identification of novel lead compounds from *A. webbiana* for plant-based antidiabetic therapies [22].

Table 1. Phytochemical Constituents of *Abies webbiana* and Their Mechanistic Role in Anti-Diabetic Activity

Compound Name	**Phytochemical Class**	**Analytical Identification**	**Reported Bioactivity**	**Mechanistic/Structural Relevance to Anti-diabetic Activity**	**Reference**
Abienol	Diterpenoid (Labdane type)	LC–MS / GC–MS	Anti-inflammatory, antioxidant, cytoprotective	Modulates cytokine signaling and ROS inhibition; structural similarity to diterpenes influencing insulin receptor and glucose transporter pathways	[51]
Limonene	Monoterpenoid	GC–MS	Antioxidant, hypoglycemic, lipid-lowering	Enhances hepatic glucose metabolism; reduces oxidative stress in pancreatic β-cells; improves adipokine balance	[52]
Camphene	Monoterpenoid	GC–MS	Antioxidant, lipid-lowering, metabolic regulatory	Reduces lipid peroxidation; improves serum lipid profiles and insulin sensitivity	[52]
α-Pinene	Monoterpenoid	GC–MS	Anti-inflammatory, antioxidant	Suppresses NF-κB activation and oxidative stress	[53]

				implicated in diabetic inflammation	
β-Pinene	Monoterpenoid	GC–MS	Antimicrobial, antioxidant	Prevents oxidative stress–induced cellular damage; potential glucose-regulatory role	[54]
Borneol	Monoterpenoid alcohol	GC–MS	Anti-inflammatory, neuroprotective	Enhances tissue glucose utilization and reduces inflammation in metabolic tissues	
Quercetin	Flavonoid	LC–MS	Antioxidant, anti-inflammatory, insulin-sensitizing	Enhances glucose uptake via GLUT4 translocation; inhibits α-glucosidase and aldose reductase	[55]
Kaempferol	Flavonoid	LC–MS	Antioxidant, hypoglycemic	Inhibits carbohydrate-hydrolyzing enzymes; improves glucose uptake in adipocytes	[55]
Gallic acid	Phenolic acid	LC–MS	Antioxidant, anti-inflammatory	Protects β-cells from oxidative stress and modulates insulin secretion	[55]
Caffeic acid	Phenolic acid	LC–MS	Antioxidant, anti-diabetic	Inhibits glucose-6-phosphatase; enhances insulin receptor sensitivity	[56]
Rutin	Flavonoid glycoside	LC–MS	Antioxidant, vasoprotective	Improves endothelial function and glucose metabolism	[56]
Saponins (mixed glycosides)	Triterpenoid glycosides	Colorimetric assay / LC–MS	Anti-hyperglycemic, lipid-lowering	Enhance insulin sensitivity; modulate lipid absorption and glucose uptake	[57]

3. In-vitro Anti-diabetic Mechanisms

3.1. Phenolic and Flavonoid Mediated Anti-Diabetic Action of *Abies webbiana*

Significant carbohydrate-hydrolysing enzymes like α-amylase, α-glucosidase, and dipeptidyl peptidase-IV (DPP-IV), which are important targets in the treatment of type 2 diabetes mellitus, have been found to exhibit substantial inhibitory effects against extracts of *A. webbiana* in in vitro enzymatic inhibition assays. The bioactive components of the plant, especially the phenolics and flavonoids, can reduce the rate of intestinal glucose absorption and avoid sudden increases in blood sugar levels after eating by inhibiting the catalytic activity of α-amylase and α-glucosidase. At the same time, glycaemic control and pancreatic insulin secretion increase when DPP-IV is inhibited because incretin hormones like glucagon-like peptide-1 (GLP-1) have their biological activity prolonged. *A. webbiana* has the ability to regulate glucose metabolism and maintain metabolic balance using its natural source of moderate multi-target inhibitors, which are highlighted by these enzymatic inhibition pathways [23].

3.2. Insulin Sensitisation through Antioxidant Pathways in *Abies webbiana*

The antioxidant-mediated insulin sensitisation capability of *A. webbiana* is crucial for its anti-diabetic effects. Polyphenolic substances, flavonoids such as quercetin and kaempferol, and terpenoids like abienol, limonene, and camphene make the plant a powerful free radical scavenger. Bioactive compounds neutralise ROS and inhibit lipid peroxidation, therby reducing damage to cellular membranes and insulin receptor complexes. *A. webbiana* reduces oxidative stress, which contributes to insulin resistance and pancreatic β-cell failure in type 2 diabetes mellitus. This preserves the functional integrity of insulin-secreting cells and insulin-responsive tissues. Additionally, antioxidant activity alters intracellular signalling pathways, including NF-κB and PPAR-γ, reducing pro-inflammatory cytokine release and improving insulin sensitivity. These biochemical and molecular effects of *A. webbiana's* antioxidants reinstate redox homeostasis, increase glucose uptake in peripheral tissues, and improve metabolic regulation, linking traditional rejuvenating and balancing claims with modern insulin-sensitising evidence [24].

3.3. Protective Role of Abies webbiana Phytoconstituents in Pancreatic β-Cell Function and Insulin Regulation

Abies webbiana has anti-diabetic potential due to its protective effect on pancreatic β-cells and ability to increase insulin production. Pancreatic β-cells in type 2 diabetes mellitus are vulnerable to oxidative stress, inflammatory cytokines, and glucotoxicity, leading to functional impairment and apoptosis. Research on β-cell lines like INS-1 and MIN6 indicates that A. webbiana phytoconstituents, including flavonoids, phenolic acids, and terpenoids, have cytoprotective effects by neutralising reactive oxygen species and decreasing nitric oxide-mediated oxidative damage. These defensive measures sustain mitochondrial integrity, cellular membranes, and the release of insulin in hyperglycaemic situations. Diterpenoid and monoterpenoid substances like abienol, camphene, and limonene may affect intracellular calcium signalling and cyclic AMP pathways, enabling glucose-stimulated insulin release. These substances create an anti-inflammatory and antioxidant environment that reduces pro-apoptotic markers like Bax and caspase-3 and increases anti-apoptotic proteins like Bcl-2, ensuring β-cell viability. A. webbiana protects pancreatic β-cells from metabolic and oxidative insults and improves their physiological function, linking its traditional use as a restorative herb to its modern pharmacological role in preserving insulin homeostasis [25].

3.4. Molecular Docking and In-Silico Validation of *Abies webbiana* Phytoconstituents for Anti-Diabetic Potential

The computational foundation for Abies webbiana phytoconstituents' experimental anti-diabetic potential is derived from molecular docking and in-silico validation investigations. The plant's bioactive chemicals' interactions with important molecular targets involved in glucose metabolism, insulin regulation, and oxidative stress pathways have been predicted and analysed using advanced molecular modelling. Compounds like abienol, limonene, camphene, quercetin, and kaempferol bind strongly to enzymes and receptors, including α-glucosidase, α-amylase, DPP-IV, PPAR-γ, and insulin receptor kinase domains, according to docking simulations. The active sites' strong hydrogen bonding, hydrophobic, and π-π stacking interactions indicate these compounds can regulate enzyme activity and receptor-mediated signalling mechanisms related to glycaemic control. Docking investigations show that abienol, a labdane-type diterpenoid, effectively interacts with DPP-IV and α-glucosidase catalytic residues, potentially reducing glucose liberation and absorption. Flavonoids, including quercetin and kaempferol, have positive docking scores with PPAR-γ and insulin receptor proteins, suggesting potential roles in increasing glucose uptake and insulin sensitivity. Computational insights corroborate in vitro biochemical results and establish a coherent framework for structure–activity relationship (SAR) analysis and lead optimisation. In-silico validation of *A. webbiana* phytoconstituents shows their pharmacophoric compatibility with established anti-diabetic targets, lending scientific credibility to its traditional therapeutic applications and enabling molecular design of natural product–based anti-diabetics [26].

3.5. Systems Pharmacology Insights into Abies webbiana's Multi-Target Mechanisms for Type 2 Diabetes Management

Recently developed network pharmacology and systems biology methods can reveal the complex, multi-target mechanisms of *Abies webbiana*, with therapeutic promise in metabolic illnesses such as type 2 diabetes. These computational frameworks link bioactive phytochemicals, biological targets, signalling pathways, and disease networks to provide an integrative view of the polypharmacological properties of plant-based treatments. A. webbiana's main constituents—abienol, quercetin, kaempferol, limonene, and camphene—have been computationally predicted to modulate a wide range of protein targets involved in insulin signalling, glucose transport, oxidative stress regulation, and inflammatory cascades [27].

These phytoconstituents affect multiple pathways, including the PI3K–Akt axis, AMPK pathway, IRS signalling, and NF-κB-mediated inflammatory response, all of which are crucial for glucose homeostasis and insulin sensitivity. A network enrichment study revealed *A. webbiana's* impact on metabolic and inflammatory networks, involving target proteins such as PPAR-γ, AKT1, INSR, MAPK8, and TNF-α. This systems-based approach supports "herbal synergy", where various phytochemicals interact with multiple targets to restore physiological homeostasis lost during diabetic aetiology [28].

Protein–protein interaction (PPI) and route topology mapping revealed that *A. webbiana*–derived compounds may regulate important nodes and hubs in oxidative balance and insulin receptor cross-talk, indicating systems-level modulation rather than biochemical suppression. Integrating transcriptome and metabolomic data into these models reveals that *A. webbiana* alters glucose metabolism, lipid oxidation, and mitochondrial function gene expression, highlighting its metabolic reprogramming potential. These observations reflect the Ayurvedic description of the plant as a systemic tonic that restores "dosha" and metabolic equilibrium, now interpreted through molecular network dynamics [29].

A. webbiana research transcends single-compound pharmacology and indicates the plant as a possible source of multi-target, pathway-interactive phytotherapeutics for complete diabetes control by integrating network and systems biology. Integrative techniques improve mechanistic understanding and help identify lead compounds and predictive biomarkers for drug discovery and clinical translation.

3.6. Molecular Network Analysis Reveals Antidiabetic Targets of *Abies webbiana*

Pathway enrichment analysis of Abies webbiana metabolites reveals the molecular networks and biological processes altered by its bioactive compounds in diabetes and metabolic dysfunction. Major phytochemical groups, including terpenoids (abienol, limonene, camphene, and α-pinene), flavonoids (quercetin, kaempferol, and rutin), and phenolic acids (gallic acid and caffeic acid), have wide-ranging impacts on metabolic and signalling pathways. Based on the KEGG, Reactome, and GO biological process databases, these metabolites are anticipated to interact with glucose utilisation, lipid metabolism, oxidative balance, and inflammatory pathways [30].

Enrichment mapping revealed considerable PI3K–Akt pathway modification, which is essential for insulin receptor activation and glucose absorption. Quercetin and kaempferol can increase PI3K–Akt–GLUT4 axis activity, improving peripheral insulin sensitivity and glycaemic management. A. webbiana's terpenoid and phenolic components also affect the AMPK signalling pathway. AMPK activation boosts fatty acid oxidation, mitochondrial biogenesis, and glucose transport, restoring energy balance in insulin-resistant conditions.

A. webbiana metabolites may influence adipocyte differentiation, lipid storage, and insulin receptor sensitivity by enhancing the insulin signalling pathway and PPAR-γ transcriptional control. NF-κB and MAPK signalling cascades, key mediators of inflammation and oxidative stress, are highly enhanced, indicating the powerful anti-inflammatory and antioxidant effects of terpenoids and polyphenols. By suppressing pro-inflammatory pathways, *A. webbiana* may reduce cytokine-induced insulin resistance [31].

Enhanced oxidative phosphorylation, glutathione metabolism, and xenobiotic detoxification pathways demonstrate the ability of plants to improve cellular redox equilibrium and mitochondrial performance. Integrating these pathways into the enrichment model indicated that *A. webbiana* modulates metabolic, inflammatory, and oxidative regulatory nodes via a systems-level mechanism. The mechanism of enrichment in *A. webbiana* metabolites shows that various phytochemicals target interconnected molecular circuits involved in glucose homeostasis, lipid control, and oxidative defense. This systems-based perspective supports its Ayurvedic significance as a metabolic harmonic and rationalises its use in modern phytotherapeutic diabetes control regimens [32].

Table 2. Molecular Targets and Pathway Mapping of Antidiabetic Phytochemicals

Major Metabolite / Phytochemical Class	Predicted Molecular Targets	Key Enriched Pathways (KEGG/Reactome)	Functional Role / Biological Implication	Reference
Quercetin (Flavonoid)	AKT1, INSR, PPARγ, GLUT4	PI3K–Akt signaling pathway, Insulin signaling, AMPK pathway	Enhances insulin sensitivity, promotes glucose uptake, regulates lipid metabolism	[58]
Kaempferol (Flavonoid)	AMPK, IRS1, MAPK1	AMPK signaling, MAPK signaling, Oxidative phosphorylation	Improves mitochondrial function, reduces oxidative stress, modulates inflammatory signaling	[59]
Rutin (Flavonoid glycoside)	G6PD, SOD1, CAT	Glutathione metabolism, ROS detoxification, Oxidative stress response	Enhances antioxidant defense and maintains redox balance	[60]
α-Pinene (Monoterpene)	NF-κB, COX-2, TNF-α	NF-κB signaling, Inflammatory mediator regulation, Cytokine–cytokine receptor interaction	Reduces inflammatory cytokines and prevents insulin resistance	[61]

Limonene (Monoterpene)	AMPK, PPARα, CPT1A	Fatty acid metabolism, AMPK signaling, PPAR regulation of lipid metabolism	Promotes fatty acid oxidation and improves energy homeostasis	[62]
Camphene (Monoterpene)	HMGCR, LPL, LDLR	Cholesterol biosynthesis, Lipid metabolism, PPAR signaling	Lowers plasma cholesterol and supports lipid regulation	[63]
Abienol (Diterpene alcohol)	IL6, TNF, NF-κB	MAPK and cytokine signaling, Inflammatory response	Suppresses inflammatory mediators and protects β-cell function	[63]
Gallic acid (Phenolic acid)	SIRT1, GPX1, CAT	Oxidative stress response, AGE–RAGE signaling, Longevity regulation pathway	Inhibits glycation, improves insulin sensitivity, and enhances antioxidant enzyme activity	[64]
Caffeic acid (Phenolic acid)	AMPK, GSK3β, IRS1	AMPK signaling, Insulin receptor cascade, Glucose metabolism	Stimulates glucose uptake and glycogen synthesis	[64]
β-Sitosterol (Phytosterol)	PPARγ, LXRα, FASN	PPAR signaling, Lipid biosynthesis, Insulin sensitivity regulation	Improves lipid utilization and insulin-mediated glucose control	[65]

3.7. Molecular Network Mechanisms of Abies webbiana in Insulin Resistance and Glucose Regulation

Network pharmacology research on *A. webbiana* phytoconstituents shows broad interactions with insulin resistance, oxidative stress, and glucose homeostasis molecular targets. Metabolites such as quercetin, kaempferol, and abienol bind to crucial signalling proteins such as PPARγ, AKT1, AMPK, and IRS1, which regulate insulin signalling and glucose uptake. These bioactive substances increase insulin receptor phosphorylation and downstream PI3K–Akt activation, promoting GLUT4 translocation to the cell membrane and peripheral glucose utilisation. Flavonoids, such as quercetin and rutin, activate the SIRT1, Nrf2, and CAT pathways, enhancing antioxidant enzyme expression and reducing ROS-induced β-cell damage. Terpenoid ingredients such as α-pinene, limonene, and abienol reduce chronic low-grade inflammation, a key determinant of insulin resistance, by targeting inflammatory mediators such as TNF-α, IL6, and NF-κB. Phenolic substances, including gallic and caffeic acid, activate the AMPK-GSK3β-GLUT4 axis, enhancing glucose metabolism and glycogen formation. These multitarget interactions demonstrate how *A. webbiana* metabolites modulate insulin signalling, oxidative balance, and metabolic regulation at the system level. This integrative mechanism combines traditional tonic and metabolic restorative claims with modern molecular comprehension, adding to the effectiveness of the plant in treating type 2 diabetes and metabolic diseases [33].

Table 3. Functional Role of Plant-Derived Compounds in Modulating Anti-Diabetic Signaling Networks

Compound / Class	**Primary Target Genes / Proteins**	**Biological Pathways Modulated**	**Functional Role in Anti-Diabetic Mechanism**	**Reference**
Quercetin	AKT1, PPARγ, IRS1, SIRT1	PI3K–Akt, AMPK, Insulin signaling	Enhances insulin sensitivity, promotes glucose uptake, reduces oxidative stress	[66]
Kaempferol	AMPK, MAPK1, GSK3β	AMPK and MAPK signaling	Regulates glycogen synthesis and energy metabolism	[67]
Rutin	CAT, GPX1, SOD1	Antioxidant response, Nrf2 signaling	Neutralizes ROS and protects pancreatic β-cells	[68]
α-Pinene	NF-κB, TNF-α, COX-2	Inflammatory response modulation	Reduces cytokine-induced insulin resistance	[66]
Limonene	PPARα, CPT1A, AMPK	Fatty acid oxidation, Lipid metabolism	Improves lipid utilization and insulin action	[66]
Abienol	IL6, NF-κB, TNF	Cytokine signaling and stress response	Suppresses inflammation and supports β-cell survival	[66]
Gallic acid	SIRT1, GPX1, CAT	AGE–RAGE, Oxidative stress pathway	Prevents glycation and enhances antioxidant defense	[66]
Caffeic acid	AMPK, GSK3β, IRS1	AMPK and glucose metabolism	Stimulates glucose uptake and glycogen storage	[66]
β-Sitosterol	PPARγ, LXRα, FASN	Lipid metabolism, Insulin regulation	Improves insulin-mediated glucose control	[66]

3.8. Network Pharmacology of *Abies webbiana* Reveals Multi-Target Anti-Diabetic Mechanisms

Integrative network modelling of *Abies webbiana* metabolites using STITCH, Cytoscape, and SwissTargetPrediction visualised phytochemical target pathway interactions underlying its potential anti-diabetic effects. Phytoconstituents, including quercetin, kaempferol, abienol, limonene, and α-pinene, were identified using LC–MS and GC–MS SwissTargetPrediction was used to discover potential human protein targets based on chemical similarity and structural homology. The predicted targets were cross-referenced and confirmed using STITCH 5.0, which builds a high-confidence compound–protein interaction (CPI) network from experimental and literature-derived interaction data [34].

Cytoscape 3.9.1 was used to visualize and analyze the interaction network, where nodes represented bioactive chemicals and protein targets, and edges represented functional or biochemical relationships. AKT1, PPARγ, AMPK, NF-κB, and SIRT1 were densely connected hub nodes in the network, indicating their crucial roles in insulin signalling, oxidative stress, and inflammation management. The MCODE and CytoHubba plug-ins revealed glucose metabolism, lipid control, and oxidative balance subnetworks through cluster and modularity analyses. These computational findings support the multi-component, multi-target therapeutic paradigm of A. webbiana, wherein structurally varied phytochemicals collectively regulate metabolic pathways [35].

These bioinformatics tools provide a systems-level depiction of the pharmacological network of A. webbiana, linking its chemical composition and physiological activity. This technique verifies traditional Ayurvedic claims using molecular data and provides a platform for rational drug design, identifying prospective lead molecules for in vitro and in vivo diabetes and metabolic disorder research.

4. Abies webbiana as a Novel Lead in Polyherbal Antidiabetic Therapeutics

Abies webbiana has been distinguished from Gymnema sylvestre, Momordica charantia, Trigonella foenum-graecum, and Tinospora cordifolia, which have antioxidant, insulin-sensitising, and enzyme-inhibitory bioactivity. A. webbiana, unlike Gymnema sylvestre (gurmar), inhibits α-glucosidase and DPP-IV, reducing postprandial hyperglycemia and improving insulin signalling through monoterpenes (e.g., limonene, α-pinene) and flavonoids (quercetin, kaempferol). Momordica charantia (bitter melon) mimics insulin function with polypeptide-p and charantin molecules, whereas A. webbiana modulates PPARγ and AMPK through terpenoid-based mechanisms, indicating a regulatory effect at the receptor and metabolic system levels [36].

Compared to Trigonella foenum-graecum (fenugreek), A. webbiana provides extensive anti-inflammatory and antioxidant protection through its phenolic and volatile oil compositions, reducing oxidative stress and improving β-cell function. Tinospora cordifolia (guduchi), rich in tinosporine and magnoflorine, acts primarily via immunomodulatory and antioxidant pathways; however, A. webbiana has a distinct advantage through neuroendocrine modulation of stress-linked glucose imbalance, as suggested by Ayurvedic aromatic inhalation (dhupa karma) that affects hypothalamic–pituitary–adrenal axis activity [37].

Comparative network pharmacology revealed that *A. webbiana* targets overlapping but unique gene and pathway clusters compared to standard anti-diabetic botanicals. The high levels of A. webbiana metabolites in the PI3K-Akt, AMPK, PPAR, and NF-κB pathways indicate their regulatory involvement in glucose metabolism, lipid balance, and oxidative stress responses. This integrative pharmacological profile represents A. webbiana as a prospective source of novel lead chemicals for metabolic disease multi-target medication development and an addition to present herbal antidiabetic medications [38].

Table 4. Integrative Mechanistic Evaluation of Phytometabolites Targeting Metabolic Pathways: The Edge of *Abies webbiana*

Plant Species	Major Bioactive Compounds	Primary Molecular Targets / Pathways	Mechanistic Highlights	Comparative Edge of *A. webbiana*	Reference
Gymnema sylvestre	Gymnemic acids, Gurmarin	β-cell regeneration, GLUT4 activation	Reduces glucose absorption and promotes insulin release	Broader antioxidant–anti-inflammatory synergy via terpenoids and flavonoids	[67]
Momordica charantia	Charantin, Polypeptide-p	Insulin receptor, PPARγ	Mimics insulin, enhances glucose utilization	Indirect modulation via PI3K–Akt and	[68]

				AMPK signaling	
Trigonella foenum-graecum	Diosgenin, Trigonelline	α-Amylase inhibition, carbohydrate metabolism	Lowers glucose absorption and improves lipid metabolism	Possesses additional neuroendocrine and oxidative modulation	[70]
Tinospora cordifolia	Tinosporine, Magnoflorine	Nrf2, NF-κB, AMPK	Immunomodulatory and antioxidant	Aromatic and adaptogenic actions influence HPA-axis and metabolic stress	[71]
Abies webbiana	Quercetin, Kaempferol, Abienol, Limonene	PPARγ, AMPK, AKT1, NF-κB	Enzyme inhibition, anti-inflammatory, β-cell protection	Multi-target synergy integrating metabolic, oxidative, and neuroendocrine regulation	[72]

By comparing *Abies webbiana* to herbal antidiabetics such as Gymnema sylvestre (gurmar), Momordica charantia (bitter melon), and Trigonella foenum-graecum (fenugreek), mechanistic similarities and phytopharmacological differences make it a promising complementary therapy. Gymnema sylvestre, rich in gymnemic acids, has hypoglycemic properties via reducing intestinal glucose absorption and promoting pancreatic β-cell regeneration. A. webbiana modulates glycemic levels by inhibiting α-glucosidase, α-amylase, and DPP-IV, lowering postprandial glucose spikes, and improving insulin receptor sensitivity via PPARγ and AMPK activation.

Momordica charantia contains insulin-like bioactives, such as charantin and polypeptide-p, that help the body absorb glucose better. Despite the absence of direct insulin mimetics, the monoterpenes (limonene and α-pinene) and diterpenoids (abienol) of A. webbiana exhibit substantial docking affinities for DPP-IV and AMPK, suggesting that the enhancement of signal transduction and attenuation of oxidative stress regulate glucose metabolism [39].

Saponins (diosgenin) and alkaloids (trigonelline) from Trigonella foenum-graecum delay gastric emptying, improve insulin sensitivity, and regulate carbohydrate metabolism, rendering it antidiabetic. A. webbiana, a unique single-mechanism botanical, inhibits enzymes, protects against inflammation, and may modulate neuroendocrine function. A. webbiana's fragrant inhalation usage in Ayurveda (dhupa or fumigation) suggests an adaptogenic effect through the hypothalamic–pituitary–adrenal (HPA) axis, indirectly altering glucose homeostasis and metabolic resilience under stress.

Gymnema sylvestre and Momordica charantia target GLUT4, PPARγ, and IRS1. However, A. webbiana phytoconstituents interact with AKT1, AMPK, NF-κB, and SIRT1, affecting glucose metabolism and oxidative and inflammatory responses. This multi-target paradigm highlights the unique role of A. webbiana as a metabolic regulator involving endocrine, oxidative, and immunological pathways [40].

Thus, benchmarking against established antidiabetic botanicals confirms A. webbiana as a next-generation, network-active herbal candidate with a polypharmacological profile and mechanistic diversity that may stimulate prospective plant-based antidiabetic drug development.

4.1. Synergistic Antidiabetic Potential of Abies webbiana in Polyherbal Formulations: A Systems Pharmacology Perspective

Through its complementary pharmacological and pharmacokinetic interactions with other antidiabetic botanicals, *Abies webbiana* can boost therapeutic efficacy in polyherbal formulations. Ayurveda and Siddha polyherbal combinations are used to maximise efficacy, decrease toxicity, and stabilise bioavailability. A. webbiana, rich in flavonoids, terpenoids, phenolics, and volatile oils, inhibits enzymes, defends against free radicals, and modulates inflammation, which are similar to the bioactivities of classical antidiabetic herbs like Gymnema sylvestre, Momordica charantia, Trigonella foenum-graecum, and Tinospora cordifolia [41].

In a composite formulation, A. webbiana's terpenoid constituents (abienol, limonene, and α-pinene) synergise with gymnemic acids from G. sylvestre and charantin from M. charantia, enhancing α-glucosidase and DPP-IV inhibition and reducing postprandial glucose spikes compared to single-herb extracts. Flavonoids, including quercetin and kaempferol, support PPARγ and AMPK activation, enhancing β-cell regeneration activity in T. cordifolia and G. sylvestre, which leads to better insulin sensitivity and secretion balance.

Polyherbal co-administration can assist with balancing redox levels in cells by neutralising reactive oxygen species (ROS) and shielding β-cells from oxidative harm, a drawback of many single-herb therapies. Aromatic and adaptogenic qualities modulate neuroendocrine function, stabilising the hypothalamic–pituitary–adrenal axis, an important but frequently overlooked metabolic regulatory element, providing stress resilience [42].

Systems biology and network pharmacology simulations indicated that polyherbal formulations containing A. webbiana exhibited a broader target network, including insulin signalling (AKT1, IRS1), glucose transport (GLUT4), inflammation (NF-κB, TNF-α), and oxidative regulation (SIRT1, Nrf2). This increased molecular interaction profile indicates phytochemical complementarity, wherein structurally distinct metabolites use overlapping yet unique pathways to produce a holistic therapeutic effect.

As an active antidiabetic agent and synergistic enhancer in multi-component herbal formulations, A. webbiana bridges pharmacological gaps between metabolic regulation, inflammatory control, and oxidative balance. Its inclusion in evidence-based polyherbal systems could lead to next-generation integrative phytomedicines for type 2 diabetes and metabolic comorbidities [43].

Table 5. Synergistic Antidiabetic Potential of *Abies webbiana* with Selected Medicinal Plants

Plant Species (Potential Combination)	Major Bioactive Compounds	Primary Mechanistic Role	Complementary Action with *Abies webbiana*	Expected Synergistic Outcome	Reference
***Gymnema sylvestre* (Gurmar)**	Gymnemic acids, Gurmarin	Suppresses glucose absorption, enhances β-cell regeneration	Terpenoids (limonene, abienol) from *A. webbiana* reinforce enzyme inhibition and	Enhanced post-prandial glucose control and β-cell protection	[73]

			insulin sensitivity		
***Momordica charantia* (Bitter melon)**	Charantin, Polypeptide-p	Mimics insulin and improves glucose uptake	Flavonoids (quercetin, kaempferol) stimulate PPARγ/AMPK pathways, complementing insulin-like actions	Dual regulation of glucose transport and signaling pathways	[74]
***Trigonella foenum-graecum* (Fenugreek)**	Diosgenin, Trigonelline	Delays gastric emptying and reduces glucose absorption	Phenolics and essential oils from *A. webbiana* modulate gut motility and enzyme secretion	Improved digestive enzyme regulation and glycemic balance	[75]
***Tinospora cordifolia* (Guduchi)**	Tinosporine, Magnoflorine	Antioxidant and immunomodulatory effects	Antioxidant flavonoids and terpenoids amplify ROS scavenging and anti-inflammatory actions	Stronger oxidative stress reduction and β-cell preservation	[75]
***Ocimum sanctum* (Holy basil)**	Eugenol, Rosmarinic acid	Modulates insulin secretion and stress response	Volatile constituents of *A. webbiana* provide neuroendocrine and adaptogenic synergy	Stress-linked glucose regulation and improved metabolic resilience	[76]
***Pterocarpus marsupium* (Indian Kino Tree)**	Pterostilbene, Marsupsin	Restores β-cell mass and enhances insulin release	*A. webbiana* supports antioxidant stabilization and enzymatic inhibition	Long-term β-cell recovery with balanced oxidative environment	[75]
***Syzygium cumini* (Jamun)**	Jamboline, Ellagic acid	Decreases glucose synthesis and	*A. webbiana* phytochemicals enhance hepatic	Hepato-protective glucose	[74]

		improves liver metabolism	AMPK activation and glucose utilization	control and improved lipid metabolism

4.2. Advancing Abies webbiana Therapeutics through Nanotechnology-Based Delivery Systems

Nanotechnology can improve the therapeutic potential of *Abies webbiana* by overcoming the poor solubility, bioavailability, and rapid metabolism of its bioactive ingredients. The controlled, prolonged, and targeted release of phytochemicals, including abienol, limonene, camphene, and quercetin, by nanocarriers improves pharmacological activity at lower doses. Polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and nanoemulsions are promising nanoformulation platforms for encapsulating and protecting bioactives from degradation while improving gastrointestinal and transdermal absorption.

Polymeric nanoparticles constructed from biodegradable polymers like PLGA, chitosan, as well as alginate can stabilise the release of *A. webbiana* phytoconstituents, increasing systemic circulation and targeted delivery to pancreatic or hepatic regions. Ligand-conjugation techniques might assist liposome-based formulations target insulin receptors with glucose transporters site-specifically. Nanoemulsions and micellar systems improve intestinal permeability and pharmacokinetics by solubilising hydrophobic terpenoids like limonene and abienol [44].

Biocompatible and extended-release solid lipid nanoparticles and nanostructured lipid carriers are useful for chronic metabolic disorders, such as diabetes. Lipid-based carriers can combine antioxidant and anti-diabetic phytochemicals, leading to synergistic formulations that combat oxidative stress, insulin resistance, and β cell dysfunction. The use of *A. webbiana* extracts to green-synthesize metallic nanoparticles, such as gold (AuNPs) and silver (AgNPs), enhances radical scavenging and glucose-lowering through catalytic surface-mediated mechanisms.

In silico pharmacokinetic modelling (ADME/T) and experimental nanocarrier design may improve dose optimization and metabolic stability, enabling preclinical and clinical use of *A. webbiana* based nanophytotherapeutics. Future directions may include the development of pH-, enzyme-, and glucose-triggered nanocarriers for precision delivery in diabetic microenvironments.

Nanoformulation-based techniques have great potential to unlock the full pharmacodynamic potential of *A. webbiana*, creating a scientifically examined bridge between traditional herbal therapy and modern nanomedicine [45].

Table 6. Emerging Nanoformulation Platforms for Phytochemical-Based Diabetes Treatment

Nano formulation Type	Representative Materials/ Carriers	Encapsulated Phytoconstituents	Mechanistic/ Pharmacological Advantage	Target Site / Application	Reference
Polymeric nanoparticles	PLGA, Chitosan, Alginate	Quercetin, Kaempferol derivatives	Controlled and sustained release; protection from enzymatic degradation; enhanced β-cell uptake	Pancreatic and hepatic tissues	[77]

Liposomes	Phosphatidylcholine, Cholesterol	Abienol, Limonene	Biocompatible lipid bilayer; improved solubility and membrane permeability; ligand-mediated targeting	Systemic circulation and insulin receptor sites	[78]
Solid Lipid Nanoparticles (SLNs)	Stearic acid, Glyceryl monostearate	Camphene, Phenolic extract	Enhanced stability, reduced burst release, improved bioavailability	Oral and transdermal delivery	[79]
Nanostructured Lipid Carriers (NLCs)	Oleic acid, Compritol 888 ATO	Mixed terpenoids	Dual lipid phase improves drug loading and controlled release	Multi-target diabetic management	[79]
Nanoemulsions / Micelles	Tween-80, Lecithin	Limonene, Abienol	Improved solubility of hydrophobic molecules; faster absorption; antioxidant synergy	Intestinal epithelium and bloodstream	[79]
Green-synthesized Metallic Nanoparticles (AgNPs, AuNPs)	Plant-mediated (aqueous *A. webbiana* extract)	Whole phytocomplex	Surface plasmon resonance enhances oxidative stress modulation and glucose uptake	Peripheral tissues; oxidative stress modulation	[79]
Stimuli-responsive nanosystems (Future direction)	pH-sensitive polymers, glucose-responsive hydrogels	Combined phytochemical formulations	Site-specific, controlled release in diabetic microenvironment; minimized side effects	Glucose-rich tissues (pancreas, muscle, adipose)	[79]

5. Bridging Ayurveda and Nanomedicine: Abies webbiana in Modern Drug Delivery

The lipophilic and volatile phytoconstituents of *Abies webbiana*, such as abienol, limonene, and camphene, are minimally bioavailable, which poses challenges for their use in medicinal applications. Inadequate aqueous solubility and rapid metabolic breakdown limit the systemic absorption and pharmacological performance of these compounds. Nanoformulation based techniques, such as the use of nanoparticles, liposomes, and phytosomes, can enhance the solubility, permeability, and retention duration of bioactives in biological systems.

Polymeric and lipid nanocarriers prolong the circulation half-life and enable targeted distribution to insulin-sensitive organs in nanoparticle-based plant terpenoid and flavonoid case studies. Liposomal encapsulation of essential oil components stabilises volatile terpenoids for sustained release with less pain. Furthermore, phytosome technology, which conjugates phytochemicals with phospholipids, has greatly improved the oral bioavailability of flavonoids, such as quercetin and kaempferol, which are key antioxidants in *A. webbiana* [46].

These advances enable *A. webbiana* based formulations to be used in nutraceutical and phytopharmaceutical products, bridging Ayurvedic wisdom with current drug delivery science. These formulations could be metabolic health supplements or adjunctive medicines for diabetes with efficacy, safety, and patient compliance. *A. webbiana* derived nanophytotherapeutics might evolve into clinically viable, next-generation natural antidiabetic treatments with nanoencapsulation optimisation and regulatory homogenisation.

5.1. Pharmacokinetic and Toxicological Evaluation of *Abies webbiana* Phytoconstituents

The pharmacological advancement of medicines derived from *Abies webbiana* requires a thorough assessment of their risk profile and pharmacokinetic characteristics to guarantee translational reliability. Initial cytotoxicity experiments performed on mammalian cell lines, including HepG2 (hepatic), L6 (myoblast), and INS-1 (pancreatic β-cells), are essential for evaluating cellular tolerance and identifying the non-cytotoxic concentration range of the bioactive components. Research on allied Pinaceae species indicates negligible cytotoxicity at therapeutic concentrations, implying that the volatile terpenoids and phenolic compounds of A. webbiana are probably harmless when properly prepared. Systematic toxicological evaluations, including acute, sub-chronic, and chronic exposure models, are crucial for validating organ-specific safety and dose-dependent reactions [47].

The pharmacokinetic profiling of *A. webbiana* metabolites can be enhanced through ADME (absorption, distribution, metabolism, and excretion) studies, offering insights into bioavailability, metabolic stability, and tissue distribution. In silico drug-likeness assessments utilising computational tools like SwissADME and pkCSM can forecast oral bioavailability, blood-brain barrier permeability, cytochrome P450 interactions, and renal excretion, thus optimising preclinical evaluation. Terpenoids, such as abienol and limonene, often display intermediate lipophilicity (logP 3–4), which promotes membrane permeability but necessitates formulation improvements, such as nanoparticle or phytosomal encapsulation, to boost solubility and systemic absorption.

Moreover, the significance of safety and dosage is crucial for transitioning *A. webbiana* based formulations from traditional applications to translational research. Standardising dosage regimens by animal toxicity studies and pharmacodynamic correlation assists in designating therapeutic windows and mitigating potential side effects. The amalgamation of pharmacokinetic modelling with clinical pharmacological characteristics may facilitate the transition from preclinical results to human applications, guaranteeing efficacy while maintaining safety. Toxicological and pharmacokinetic assessments will establish the biocompatibility of *A. webbiana* phytoconstituents and endorse their incorporation into contemporary phytopharmaceutical and nutraceutical formulations [48].

Table 7. Predicted Pharmacokinetic and Safety Profile of Abies webbiana Phytoconstituents

Parameter	Phytoconstituent / Extract	Experimental or Predicted Findings	Pharmacological / Safety Implication	Reference

Cytotoxicity (in vitro)	Ethanolic / Methanolic leaf extract	Non-cytotoxic up to 200 µg/mL in HepG2 and L6 cell lines	Indicates safety margin for therapeutic formulation	[80]
Acute oral toxicity (in vivo)	Whole extract	LD_{50} > 2000 mg/kg (predicted, OECD guideline)	Classified as non-toxic; suitable for oral applications	[81]
Sub-chronic toxicity	Phenolic and terpenoid fraction	No observable adverse effect level (NOAEL) predicted at moderate doses	Safe for repeated dosing in nutraceutical formulations	[80]
Lipophilicity (LogP)	Abienol (3.6), Limonene (3.1), Camphene (2.8)	Moderate lipophilicity supports membrane permeability	Enhances bioavailability through lipid-based carriers	[82]
Oral bioavailability (SwissADME)	Quercetin, Kaempferol derivatives	0.35–0.55 predicted bioavailability score	Moderate absorption; improved with phospholipid conjugation	[81]
Metabolic stability (CYP450 interaction)	Limonene, Abienol	Weak CYP3A4 substrate potential; minimal inhibition risk	Favors multi-drug compatibility	[82]
Excretion (pkCSM prediction)	Mixed terpenoid fraction	Predominantly renal clearance with moderate half-life	Supports safe elimination and reduced accumulation	[83]
Drug-likeness (Lipinski's Rule)	All major constituents	≤ 5 H-bond donors, ≤ 10 acceptors, MW < 500	Satisfies criteria for oral drug candidacy	[83]
Safety classification (overall)	Crude extract and bioactives	Non-mutagenic, non-carcinogenic, non-hepatotoxic (predicted)	Demonstrates favorable safety profile for translational research	[83]

5.2. Unveiling the Molecular and Therapeutic Promise of *Abies webbiana* in Metabolic Disorders

Abies webbiana has significant pharmacological and therapeutic potential; however, considerable obstacles and knowledge gaps prevent its conversion into validated anti-diabetic therapies. The lack of in vivo validation and clinical proof is a major constraint. Numerous in vitro and in silico investigations have shown antioxidant, anti-inflammatory, and enzyme-inhibitory properties; however, animal models and human trials are needed to confirm these findings. In metabolic illnesses, including type 2 diabetes mellitus, efficacy, dose safety, and therapeutic periods must be validated by rigorous in vivo pharmacodynamic and pharmacokinetic studies and phase I–III clinical trials [49].

The standardisation and molecular characterisation of plant-derived bioactives are additional challenges. Pharmaceutical results are often unreliable because of changes in phytochemical composition related to environmental conditions, seasonal variation, and extraction methods. Reproducibility and regulatory compliance require standardised extraction, purification, and quantification techniques using modern analytical platforms like LC-MS/MS, NMR spectroscopy, and high-resolution chromatography. Identifying biomarker-based quality control measures and expanding the structure–activity correlations (SAR) of terpenoids 'and flavonoids' will strengthen the molecular basis of A. webbiana's bioefficacy.

Modern technology may circumvent these obstacles. Lead bioactives and their molecular targets can be discovered faster using AI-based chemical screening and omics-driven validation methods, including transcriptomics, metabolomics, and proteomics. Machine learning algorithms and network pharmacology tools, such as STITCH, SwissTargetPrediction, and Cytoscape Modelling, can predict multi-target interactions, optimize pharmacokinetics, and identify synergistic phytochemical combinations. Systems biology mechanisms can map the metabolic and signalling networks altered by A. webbiana ingredients to better understand their therapeutic activity [50].

Future research might create standardised nano-formulated and phytopharmaceutical compounds using validated pharmacological and toxicological databases. Traditional medicine practitioners, molecular biologists, and pharmacologists may act synergistically to translate A. webbiana from ethnomedicine to evidence-based therapy. Bridging cultural understanding with cutting-edge molecular technology could enhance the clinical usefulness of *A. webbiana* and make it a promising option for next-generation natural anti-diabetic therapies.

Table 8. Translational Strategies for Herbal Therapeutics: Addressing Validation, Standardization, and Bioavailability Gaps

Identified Challenge / Knowledge Gap	**Underlying Cause or Limitation**	**Proposed Research Approach / Solution**	**Expected Outcome / Impact**	**Reference**
Lack of in-vivo and clinical validation	Most studies limited to in-vitro or in-silico models; absence of standardized animal or human trials	Conduct in-vivo pharmacodynamic and toxicological studies; initiate preclinical–clinical transition (Phase I–III)	Establishes scientific validation, dosage safety, and therapeutic efficacy	[84]
Phytochemical variability and poor standardization	Environmental, seasonal, and extraction-based variations alter bioactive concentration	Develop standardized extraction protocols; employ LC-MS/MS, HPLC, and NMR-based fingerprinting	Ensures reproducibility and regulatory acceptance	[84]
Incomplete molecular	Limited identification of structure–	Utilize high-resolution spectroscopic and	Clarifies mechanistic pathways and	[84]

characterization of bioactives	activity relationships (SAR)	docking studies to define molecular interactions	strengthens drug discovery rationale	
Limited bioavailability of lipophilic compounds	Poor solubility and metabolic instability of terpenoids and flavonoids	Employ nanoformulations, phytosomes, and advanced delivery systems	Enhances absorption, bioavailability, and target specificity	[84]
Lack of integrated multi-omics data	Insufficient use of systems biology in herbal research	Apply metabolomic, transcriptomic, and proteomic profiling of *A. webbiana* extracts	Enables holistic understanding of mechanism and target pathways	[85]
Need for AI-based compound prioritization	Manual screening of phytochemicals is time-consuming and fragmented	Integrate AI and machine learning for predictive compound screening and pharmacokinetic optimization	Accelerates identification of lead molecules and formulation design	[86]
Regulatory and translational challenges	Absence of globally accepted guidelines for herbal nanomedicines	Align formulation and toxicology protocols with WHO and ICH phytopharmaceutical standards	Facilitates commercialization and clinical adoption	[86]
Ethnopharmacological validation gaps	Disconnection between traditional use data and modern evidence	Conduct community-linked ethnopharmacological documentation and comparative analysis	Preserves indigenous knowledge while supporting scientific integration	[87]

Conclusion & Future perspective

Among the many obscure potential natural anti-diabetic treatments, *Abies webbiana* stands out as a pharmacologically rich member of the Pinaceae family. Modern pharmacological research supports its historical use in treating respiratory, inflammatory, and metabolic problems, which have their origins in ancient Ayurvedic and tribal medicine. The bioactive phytoconstituents of this plant, including flavonoids, phenolics, and terpenoids, confer potent antioxidant, anti-inflammatory, and enzyme-inhibitory properties. These characteristics are mechanistically related to the pathophysiological features of type 2 diabetes mellitus. Recent results from in silico, network pharmacology, and in vitro studies support its ability to influence insulin resistance, oxidative stress, and glucose metabolism via interactions with several targets.

However, more translational studies and thorough mechanistic validation are necessary to fully realize the medicinal potential of *A. webbiana*. The effectiveness, bioavailability, and safety of future investigations in both preclinical and clinical settings will depend on how well molecular biology, bioinformatics, and nanotechnology-based delivery methods are combined. A potential solution to the current division between traditional medicinal practices and modern drug discovery methods is the standardisation of phytochemical profiles in conjunction with omics-driven and AI-assisted compound discovery.

Therefore, the transformation of traditional phytotherapy into mechanism-driven phytopharmaceuticals has never been more evident than that with *Abies webbiana*. This Himalayan conifer has the potential to transform from a beloved herbal cure into a cutting-edge natural therapeutic agent for the treatment and prevention of diabetes and associated metabolic diseases with the aid of constant multidisciplinary cooperation and a focus on translation.

References

1. Huang, Q., Li, Y., Yu, M., Lv, Z., Lu, F., Xu, N., ... & Jiang, H. (2025). Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, and forecasts to 2050. *Frontiers in Endocrinology*, *16*, 1538143.
2. Bhusal, L., Hegde, C. T., Srivastava, A., & Rakesh, T. (2025). THERAPEUTIC POTENTIAL OF KANAKASAVA IN PURVIEW OF BRONCHIAL ASTHMA: A REVIEW.
3. Ghosh, A. K., Sen, D., & Bhattacharya, S. (2010). A new alkaloid isolated from Abies webbiana leaf. *Pharmacognosy Research*, *2*(3), 186.
4. Al Kury, L. T., Abdoh, A., Ikbariah, K., Sadek, B., & Mahgoub, M. (2021). In vitro and in vivo antidiabetic potential of monoterpenoids: An update. *Molecules*, *27*(1), 182.
5. Fang, J. Y., Lin, C. H., Huang, T. H., & Chuang, S. Y. (2019). In vivo rodent models of type 2 diabetes and their usefulness for evaluating flavonoid bioactivity. *Nutrients*, *11*(3), 530.
6. Mehta, K., Maass, C., Cucurull-Sanchez, L., Pichardo-Almarza, C., Subramanian, K., Androulakis, I. P., ... & Sherwin, C. M. (2025). Modernizing Preclinical Drug Development: The Role of New Approach Methodologies. *ACS Pharmacology & Translational Science*.
7. Tran, N., Pham, B., & Le, L. (2020). Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. *Biology*, *9*(9), 252.
8. Arora, P., & AA, S. A. (2019). A Mini Review on Abies Webbiana Lindl.: A Medicinally Important Plant of India. *Am J Pharm Heal Res*, *7*(8), 2321-3647.
9. Timothy, C. N., Nandhini, J. T., Varghese, S. S., & Rajeshkumar, S. (2021). Abies webbiana ethanolic extract based mouthwash and its antimicrobial and cytotoxic effect. *Journal of Pharmaceutical Research International*, *33*(62), 371-385.
10. Anand, U., Tudu, C. K., Nandy, S., Sunita, K., Tripathi, V., Loake, G. J., ... & Proćków, J. (2022). Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives–A review. *Journal of ethnopharmacology*, *284*, 114744.
11. Ghimire, B., Lee, C., Yang, J., & Heo, K. (2015). Comparative leaf anatomy of some species of Abies and Picea (Pinaceae). *Acta Botanica Brasilica*, *29*(3), 346-353.
12. Usmani, K., Jain, S. K., & Yadav, S. (2023). Mechanism of action of certain medicinal plants for the treatment of asthma. *Journal of Ethnopharmacology*, *317*, 116828.
13. Tiwari, A., Kunwar, R. M., Bussmann, R. W., Paniagua-Zambrana, N. Y., Hussain, W., & Abbasi, A. M. (2021). Abies pindrow (Royle ex D. Don.) Royle Abies spectabilis (D. Don) Spach Pinaceae. In *Ethnobotany of the Himalayas* (pp. 1-11). Cham: Springer International Publishing.
14. Gaonkar, V. P., & Hullatti, K. (2020). Indian Traditional medicinal plants as a source of potent Anti-diabetic agents: A Review. *Journal of diabetes & metabolic disorders*, *19*(2), 1895-1908.

15. Zhang, H., & Tsao, R. (2016). Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. *Current Opinion in Food Science*, *8*, 33-42.
16. Chettri, D., & Verma, A. K. (2023). Biological significance of carbohydrate active enzymes and searching their inhibitors for therapeutic applications. *Carbohydrate Research*, *529*, 108853.
17. Lentle, R. G., Reynolds, G. W., & Janssen, P. W. M. (2013). Gastrointestinal tone; its genesis and contribution to the physical processes of digestion. *Neurogastroenterology & Motility*, *25*(12), 931-942.
18. Arora, P., & AA, S. A. (2019). A Mini Review on Abies Webbiana Lindl.: A Medicinally Important Plant of India. *Am J Pharm Heal Res*, *7*(8), 2321-3647.
19. Bhattarai, K., Bhattarai, R., Pandey, R. D., Paudel, B., & Bhattarai, H. D. (2024). A comprehensive review of the phytochemical constituents and bioactivities of Ocimum tenuiflorum. *The Scientific World Journal*, *2024*(1), 8895039.
20. Saini, R. K., Ranjit, A., Sharma, K., Prasad, P., Shang, X., Gowda, K. G. M., & Keum, Y. S. (2022). Bioactive compounds of citrus fruits: A review of composition and health benefits of carotenoids, flavonoids, limonoids, and terpenes. *Antioxidants*, *11*(2), 239.
21. Soulimani, R., Bouayed, J., & Joshi, R. K. (2019). Limonene: natural monoterpene volatile compounds of potential therapeutic interest. *American Journal of Essential Oils and Natural Products*, *7*(4), 01-10.
22. Beck, A. G., Muhoberac, M., Randolph, C. E., Beveridge, C. H., Wijewardhane, P. R., Kenttamaa, H. I., & Chopra, G. (2024). Recent developments in machine learning for mass spectrometry. *ACS Measurement Science Au*, *4*(3), 233-246.
23. Okechukwu, P., Sharma, M., Tan, W. H., Chan, H. K., Chirara, K., Gaurav, A., & Al-Nema, M. (2020). In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes. *Pharmacia*, *67*, 363-371.
24. Clemente-Suárez, V. J., Martín-Rodríguez, A., Beltrán-Velasco, A. I., Rubio-Zarapuz, A., Martínez-Guardado, I., Valcarcel-Martin, R., & Tornero-Aguilera, J. F. (2025). Functional and Therapeutic Roles of Plant-Derived Antioxidants in Type 2 Diabetes Mellitus: Mechanisms, Challenges, and Considerations for Special Populations. *Antioxidants*, *14*(6), 725.
25. Yedjou, C. G., Grigsby, J., Mbemi, A., Nelson, D., Mildort, B., Latinwo, L., & Tchounwou, P. B. (2023). The management of diabetes mellitus using medicinal plants and vitamins. *International journal of molecular sciences*, *24*(10), 9085.
26. Baruah, R. R., & Patle, D. (2025). Computational and biological perspective of phytoconstituents and their synthetic derivatives in antidiabetic therapy. *Letters in Drug Design & Discovery*, 100060.
27. Li, L., & Kar, S. (2025). Leveraging network pharmacology for drug discovery: Integrative approaches and emerging insights. *Medicine in Drug Discovery*, 100220.
28. Huang, X., Liu, G., Guo, J., & Su, Z. (2018). The PI3K/AKT pathway in obesity and type 2 diabetes. *International journal of biological sciences*, *14*(11), 1483.
29. Akbarzadeh, S., Coşkun, Ö., & Günçer, B. (2024). Studying protein–protein interactions: Latest and most popular approaches. *Journal of structural biology*, *216*(4), 108118.
30. Chicco, D., & Agapito, G. (2022). Nine quick tips for pathway enrichment analysis. *PLoS computational biology*, *18*(8), e1010348.

31. Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., Fakhri, F., ... & Samarghandian, S. (2022). AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. *Biomedicine & Pharmacotherapy*, *146*, 112563.
32. Chen, T. H., Wang, H. C., Chang, C. J., & Lee, S. Y. (2024). Mitochondrial glutathione in cellular redox homeostasis and disease manifestation. *International journal of molecular sciences*, *25*(2), 1314.
33. Singirala, S. K., Dubey, P. K., & Roy, S. (2025). Extraction of Bioactive Compounds From Withania somnifera: The Biological Activities and Potential Application in the Food Industry: A Review. *International Journal of Food Science*, *2025*(1), 9922626.
34. Kuhn, M., von Mering, C., Campillos, M., Jensen, L. J., & Bork, P. (2007). STITCH: interaction networks of chemicals and proteins. *Nucleic acids research*, *36*(suppl_1), D684-D688.
35. Doncheva, N. T., Morris, J. H., Gorodkin, J., & Jensen, L. J. (2018). Cytoscape StringApp: network analysis and visualization of proteomics data. *Journal of proteome research*, *18*(2), 623-632.
36. Patel, D. K., Prasad, S. K., Kumar, R., & Hemalatha, S. (2012). An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pacific journal of tropical biomedicine*, *2*(4), 320-330.
37. Akhtar, H., Ali, Y. A., Wei, C. R., Albassam, R. S., Ahmed, F., Yasmin, A., ... & Ndagire, C. T. (2025). Bioactive Potential and Health Benefits of Trigonella foenum-graecum L.: A Comprehensive Review. *Food Science & Nutrition*, *13*(9), e70887.
38. Yasin, M., Hussain Janbaz, K., Imran, I., Gilani, A. U. H., & Bashir, S. (2014). Pharmacological studies on the antispasmodic, bronchodilator and anti-platelet activities of Abies webbiana. *Phytotherapy Research*, *28*(8), 1182-1187.
39. Rawat Mukesh, R. M., & Parmar Namita, P. N. (2013). Medicinal plants with antidiabetic potential-a review.
40. Pathak, N., & Negi, A. S. (2024). Plant based steroidal and triterpenoid sapogenins: Chemistry on diosgenin and biological aspects. *European Journal of Medicinal Chemistry*, *279*, 116915.
41. Rajini, P. S., & Muralidhara, M. (2023). Therapeutic efficacy of ayurvedic polyherbal formulations (PHF): Interactive mechanisms and broad-spectrum activities against neurological disorders. In *Ayurvedic herbal preparations in neurological disorders* (pp. 89-111). Academic Press.
42. Sharma, P., Nandave, M., Nandave, D., Yadav, S., Vargas-De-La-Cruz, C., Singh, S., ... & Behl, T. (2023). Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants. *American Journal of Translational Research*, *15*(11), 6321.
43. Mukherjee, P. K., Banerjee, S., & Kar, A. (2021). Molecular combination networks in medicinal plants: understanding synergy by network pharmacology in Indian traditional medicine. *Phytochemistry reviews*, *20*(4), 693-703.
44. Sabir, S., Thani, A. S. B., & Abbas, Q. (2025). Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance. *Frontiers in Bioengineering and Biotechnology*, *13*, 1548588.
45. Sangeetha, S., & Narayanasamy, D. (2024). The science of solid lipid nanoparticles: from fundamentals to applications. *Cureus*, *16*(9).

46. Sevindik, M., Khassanov, V. T., Gürgen, A., Sevindik, E., & Uysal, İ. (2025). A comprehensive review on chemical and phenolic composition and biological activities of Abies species. *Studies in Natural Products Chemistry*, *85*, 223-248.
47. Bhardwaj, K., Silva, A. S., Atanassova, M., Sharma, R., Nepovimova, E., Musilek, K., ... & Kuča, K. (2021). Conifers phytochemicals: A valuable forest with therapeutic potential. *Molecules*, *26*(10), 3005.
48. Radosavljevic, M., Svob Strac, D., Jancic, J., & Samardzic, J. (2023). The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. *Genes*, *14*(5), 1095.
49. Kim, J., & Park, E. J. (2018). Chemical and biological properties of the genus Abies. In *Advances in Plant Phenolics: From Chemistry to Human Health* (pp. 225-236). American Chemical Society.
50. Kisiriko, M., Anastasiadi, M., Terry, L. A., Yasri, A., Beale, M. H., & Ward, J. L. (2021). Phenolics from medicinal and aromatic plants: Characterisation and potential as biostimulants and bioprotectants. *Molecules*, *26*(21), 6343.
51. Mohammed, A., Tajuddeen, N., Ibrahim, M. A., Isah, M. B., Aliyu, A. B., & Islam, M. S. (2022). Potential of diterpenes as antidiabetic agents: Evidence from clinical and pre-clinical studies. *Pharmacological Research*, *179*, 106158.
52. Murali, R., Karthikeyan, A., & Saravanan, R. (2013). Protective effects of D-limonene on lipid peroxidation and antioxidant enzymes in streptozotocin-induced diabetic rats. *Basic & clinical pharmacology & toxicology*, *112*(3), 175-181.
53. Choghakhori, R., Azadpour, M., Abbasnezhad, A., Ebrahimzadeh, F., & Ahmadvand, H. (2024). The protective effects of alpha-pinene on high glucose-induced oxidative stress and inflammation in HepG2 cells. *Iranian Journal of Basic Medical Sciences*, *27*(8), 967.
54. Santos, E. S., Abrantes Coelho, G. L., Saraiva Fontes Loula, Y. K., Saraiva Landim, B. L., Fernandes Lima, C. N., Tavares de Sousa Machado, S., ... & Kerntopf, M. R. (2022). Hypoglycemic, Hypolipidemic, and Anti-Inflammatory Effects of Beta-Pinene in Diabetic Rats. *Evidence-Based Complementary and Alternative Medicine*, *2022*(1), 8173307.
55. Eid, H. M., Nachar, A., Thong, F., Sweeney, G., & Haddad, P. S. (2015). The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes. *Pharmacognosy magazine*, *11*(41), 74.
56. Ghorbani, A. (2017). Mechanisms of antidiabetic effects of flavonoid rutin. *Biomedicine & Pharmacotherapy*, *96*, 305-312.
57. El Barky, A. R., Hussein, S. A., Alm-Eldeen, A. E., Hafez, Y. A., & Mohamed, T. M. (2017). Saponins and their potential role in diabetes mellitus. *Diabetes Manag*, *7*(1), 148-58.
58. Dhanya, R., Arya, A. D., Nisha, P., & Jayamurthy, P. (2017). Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line. *Frontiers in pharmacology*, *8*, 336.
59. Alrumaihi, F., Almatroodi, S. A., Alharbi, H. O. A., Alwanian, W. M., Alharbi, F. A., Almatroudi, A., & Rahmani, A. H. (2024). Pharmacological potential of kaempferol, a flavonoid in the management of pathogenesis via modulation of inflammation and other biological activities. *Molecules*, *29*(9), 2007.
60. Vinayagam, R., & Xu, B. (2015). Antidiabetic properties of dietary flavonoids: a cellular mechanism review. *Nutrition & metabolism*, *12*(1), 60.
61. Al Kury, L. T., Abdoh, A., Ikbariah, K., Sadek, B., & Mahgoub, M. (2021). In vitro and in vivo antidiabetic potential of monoterpenoids: An update. *Molecules*, *27*(1), 182.

62. Sousa, L. D. R., Viana, N. R., Coêlho, A. G., Barbosa, C. D. O., Barros, D. S. L., Martins, M. D. C. D. C. E., ... & Arcanjo, D. D. R. (2023). Use of monoterpenes as potential therapeutics in diabetes mellitus: A prospective review. *Advances in Pharmacological and Pharmaceutical Sciences*, *2023*(1), 1512974.
63. Akpoveso, O. O. P., Ubah, E. E., & Obasanmi, G. (2023). Antioxidant phytochemicals as potential therapy for diabetic complications. *Antioxidants*, *12*(1), 123.
64. Al-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., & Büsselberg, D. (2019). Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. *Biomolecules*, *9*(9), 430.
65. Bouyahya, A., Bakrim, S., Aboulaghras, S., El Kadri, K., Aanniz, T., Khalid, A., ... & El Omari, N. (2024). Bioactive compounds from nature: Antioxidants targeting cellular transformation in response to epigenetic perturbations induced by oxidative stress. *Biomedicine & Pharmacotherapy*, *174*, 116432.
66. Yi, H., Peng, H., Wu, X., Xu, X., Kuang, T., Zhang, J., ... & Fan, G. (2021). The therapeutic effects and mechanisms of quercetin on metabolic diseases: pharmacological data and clinical evidence. *Oxidative medicine and cellular longevity*, *2021*(1), 6678662.
67. Moore, W. T., Luo, J., & Liu, D. (2023). Kaempferol improves glucose uptake in skeletal muscle via an AMPK-dependent mechanism. *Food Science and Human Wellness*, *12*(6), 2087-2094.
68. Harooni, E., Radmehr, V., Razliqi, R. N., Ahangarpour, A., & Bazyar, H. (2025). Rutin Protects Pancreatic Islets Against Methylglyoxal-Induced Oxidative Stress and Elevates Insulin Secretion. *Gazi Medical Journal*.
69. Kashif, M., Nasir, A., Gulzaman, Rafique, M. K., Abbas, M., ur Rehman, A., ... & Mtewa, A. G. (2023). Unlocking the anti-diabetic potential of Gymnema sylvestre, Trigonella foenum-graecum, and their combination thereof: An in-vivo evaluation. *Food Science & Nutrition*, *11*(12), 7664-7672.
70. Oyelere, S. F., Ajayi, O. H., Ayoade, T. E., Pereira, G. B. S., Owoyemi, B. C. D., Ilesanmi, A. O., & Akinyemi, O. A. (2022). A detailed review on the phytochemical profiles and anti-diabetic mechanisms of Momordica charantia. *Heliyon*, *8*(4).
71. Khanal, P., Patil, B. M., Mandar, B. K., Dey, Y. N., & Duyu, T. (2019). Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia. *Clinical Phytoscience*, *5*(1), 35.
72. Zirari, M., Aouji, M., Imtara, H., Hmouni, D., Tarayrah, M., Noman, O. M., & El Mejdoub, N. (2024). Nutritional composition, phytochemicals, and antioxidant activities of Abies marocana Trab. needles. *Frontiers in Sustainable Food Systems*, *8*, 1348141.
73. Saqulain, S., Verma, M., Singh, H., Dharmalingam, S., MJ, E., Srivastav, Y., ... & Kumar, A. (2025). Therapeutic role of Gymnema sylvestre and Momordica charantia in diabetes management: a detailed review of their mechanisms in insulin resistance, glucose metabolism regulation, and clinical efficacy in type 2 diabetes mellitus. *Int J Pharm Sci*, *3*, 1757-68.
74. Tran, N., Pham, B., & Le, L. (2020). Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. *Biology*, *9*(9), 252.
75. Rizvi, S. I., & Mishra, N. (2013). Traditional Indian medicines used for the management of diabetes mellitus. *Journal of diabetes research*, *2013*(1), 712092.
76. Pattanayak, P., Behera, P., Das, D., & Panda, S. K. (2010). Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview. *Pharmacognosy reviews*, *4*(7), 95.

77. Zolkepli, H., Widodo, R. T., Mahmood, S., Salim, N., Awang, K., Ahmad, N., & Othman, R. (2022). A review on the delivery of plant-based antidiabetic agents using nanocarriers: current status and their role in combatting hyperglycaemia. *Polymers*, *14*(15), 2991.
78. Dinić, S., Arambašić Jovanović, J., Uskoković, A., Jovanović, A., Grdović, N., Rajić, J., ... & Mihailović, M. (2024). Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin. *Pharmaceutics*, *16*(6), 801.
79. Foudah, A. I., Salkini, M. A., Alqarni, M. H., & Alam, A. (2024). Preparation and evaluation of antidiabetic activity of mangiferin-loaded solid lipid nanoparticles. *Saudi Journal of Biological Sciences*, *31*(4), 103946.
80. Vučkovski, M., Filipović, A., Jadranin, M., Koričanac, L., Žakula, J., Bondžić, B. P., & Bondžić, A. M. (2024). Enhanced Bioactivity of Quercetin–Tetrahydroisoquinoline Derivatives: Effect on Lipophilicity, Enzymes Inhibition, Antioxidant Potential, and Cytotoxicity. *International Journal of Molecular Sciences*, *25*(23), 13076.
81. Dos Santos, M. G., Demonceaux, M., Schimith, L. E., Goux, M., Solleux, C., Muccillo-Baisch, A. L., ... & Hort, M. A. (2025). Pharmacokinetic Prediction and Cytotoxicity of New Quercetin Derivatives. *Chemistry & Biodiversity*, e202500119.
82. Rinaldi de Alvarenga, J. F., Lei Preti, C., Santos Martins, L., Noronha Hernandez, G., Genaro, B., Lamesa Costa, B., ... & Fiamoncini, J. (2022). Identification of d-limonene metabolites by lc-hrms: An exploratory metabolic switching approach in a mouse model of diet-induced obesity. *Metabolites*, *12*(12), 1246.
83. Batiha, G. E. S., Beshbishy, A. M., Ikram, M., Mulla, Z. S., El-Hack, M. E. A., Taha, A. E., ... & Elewa, Y. H. A. (2020). The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: quercetin. *Foods*, *9*(3), 374.
84. Heinrich, M., Jalil, B., Abdel-Tawab, M., Echeverria, J., Kulić, Ž., McGaw, L. J., ... & Wang, J. B. (2022). Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research—the ConPhyMP—guidelines. *Frontiers in Pharmacology*, *13*, 953205.
85. Builders, P. F. (2018). Introductory chapter: Introduction to herbal medicine. *Herbal medicine*, 1-9.
86. Teja, P. K., Mithiya, J., Kate, A. S., Bairwa, K., & Chauthe, S. K. (2022). Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview. *Phytomedicine*, *96*, 153890.
87. Alum, E. U., Manjula, V. S., Uti, D. E., Echegu, D. A., Ugwu, O. P. C., Egba, S. I., & Agu, P. C. (2025). Metabolomics-driven standardization of herbal medicine: advances, applications, and sustainability considerations. *Natural Product Communications*, *20*(8), 1934578X251367650.